PathoDNA, an Advanced Diagnostic for Lyme Disease &Co-Infections Utilizing Next Generation DNA Sequencing with Greater Sensitivity and Selectivity than ELISA/Western Blot  

作　　者：Robert Schettig Ruth Tan-Lim Daniel Warren Zachary Poteet Rory Sears Michael Hummel Connor Coffin Kendra Quart Christopher Aussems Ronald Matthias Jr. David Medina Matthew Klein Gayle Roberts John C. Oertle III Dino Prato Robert Schettig;Ruth Tan-Lim;Daniel Warren;Zachary Poteet;Rory Sears;Michael Hummel;Connor Coffin;Kendra Quart;Christopher Aussems;Ronald Matthias Jr.;David Medina;Matthew Klein;Gayle Roberts;John C. Oertle III;Dino Prato(Envita, Scottsdale, USA)

机构地区：[1]Envita, Scottsdale, USA

出　　处：《Advances in Infectious Diseases》2021年第4期405-429,共25页传染病进展（英文）

摘　　要：The controversial subject of chronic Lyme disease has occupied medical discourse for years while contributing to unprecedented patient suffering in the United States and abroad. A general misunderstanding of Lyme disease and overconfidence in the Center for Disease Control’s (CDC) recommended two-step test for Lyme disease has led to misdiagnosis and incorrect treatment over the years. This leads to increasing medical expenses and worse outcomes for patients. The two-step test, an ELISA immunoblot followed by a confirmatory Western blot, yields accuracy rates as low as 29% for acute Lyme disease and 75% for chronic Lyme disease. While these practices have been a staple of microbiology for decades, these accuracy rates are unacceptable for diagnostic tests when better technology is available. PathoDNA, a Next-Generation DNA sequencing test for Lyme disease and other tick-borne pathogens, achieves accuracy rates of 98% for <em>B. burgdorferi</em> and 95% or greater for other common tick-borne pathogens with superior sensitivity and selectivity. PathoDNA is a Clinical Laboratory Improvement and Amendments (CLIA)-validated laboratory test that achieves these results utilizing Next Generational DNA Sequencing and a proprietary bioinformatics database. Thus, it allows for rapid results and specific identification of tick-borne illnesses. In this article, we will compare this promising technology against the existing standards for diagnosing and testing Lyme disease. We believe that PathoDNA can set a new standard for identifying <em>Borrelia</em> and diagnosing Lyme disease along with other tick-borne infections.The controversial subject of chronic Lyme disease has occupied medical discourse for years while contributing to unprecedented patient suffering in the United States and abroad. A general misunderstanding of Lyme disease and overconfidence in the Center for Disease Control’s (CDC) recommended two-step test for Lyme disease has led to misdiagnosis and incorrect treatment over the years. This leads to increasing medical expenses and worse outcomes for patients. The two-step test, an ELISA immunoblot followed by a confirmatory Western blot, yields accuracy rates as low as 29% for acute Lyme disease and 75% for chronic Lyme disease. While these practices have been a staple of microbiology for decades, these accuracy rates are unacceptable for diagnostic tests when better technology is available. PathoDNA, a Next-Generation DNA sequencing test for Lyme disease and other tick-borne pathogens, achieves accuracy rates of 98% for <em>B. burgdorferi</em> and 95% or greater for other common tick-borne pathogens with superior sensitivity and selectivity. PathoDNA is a Clinical Laboratory Improvement and Amendments (CLIA)-validated laboratory test that achieves these results utilizing Next Generational DNA Sequencing and a proprietary bioinformatics database. Thus, it allows for rapid results and specific identification of tick-borne illnesses. In this article, we will compare this promising technology against the existing standards for diagnosing and testing Lyme disease. We believe that PathoDNA can set a new standard for identifying <em>Borrelia</em> and diagnosing Lyme disease along with other tick-borne infections.

关 键 词：Lyme Disease TICKS TICK-BORNE Borrelia Sequencing Diagnosis 

分 类 号：R73[医药卫生—肿瘤]